{
  "id": "fda_guidance_chunk_0165",
  "title": "Introduction - Part 165",
  "text": "the composite endpoint are important (see section III.D.) and can influence interpretation of the overall study results. The examination of the components is always necessary, but whether multiplicity adjustment should be made depends on the purpose. If the intent is to better understand the demonstrated effect on the composite, then no adjustment is recommended. In that case, clinical judgment is used to decide whether the benefit is clinically meaningful and exceeds risk, and how it will be described in the FDA-approved labeling. If the intent is to establish additional effects of the drug, then multiplicity adjustment should be made. 4. Multi-Component Endpoints A multi-component endpoint is a within-subject combination of two or more components. In this endpoint, an individual subjectâ€™s evaluation is dependent upon observation of all the specified components in that subject. A single overall rating or status is then determined according to specified rules. A single overall rating can be formed by some kind of average (either weighted or unweighted) across the individual domain scores. An example of a multi-component endpoint is the Positive and Negative Syndrome Scale (PANSS) in schizophrenia research. A multi-component endpoint can also be a dichotomous (response) endpoint corresponding to an individual subject achieving specified criteria on each of the multiple components. For example, the primary endpoint in clinical trials of allogeneic pancreatic islet cells for Type 1 diabetes mellitus can be a response rate in which subjects are considered responders only if they meet two dichotomous response criteria: normal range of HbA1c and elimination of hypoglycemia. There are more complex endpoint formulations where several, but not all, different features of a disease must be positively affected for a subject to be regarded as receiving benefit. For example, a positive response for an individual subject might be defined as a certain degree of improvement in two specific aspects of a disease along with improvement in at least three out of five additional disease features, as in the American College of Rheumatology (ACR) scoring system for rheumatoid arthritis. The use of within-subject multi-component endpoints may be efficient if the treatment effects on the different components are generally trending in the same direction within a subject. Study power can be adversely affected, however, if there is limited concordance among the endpoints. Although multi-component endpoints can provide some gains in efficiency",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 220416,
  "end_pos": 221952,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "statistical",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.688Z"
}